Endocrinology and metabolism clinics of North America

New Drug Treatments for Managing Obesity

Updated

Abstract

Seven FDA-approved anti-obesity medications may support long-term weight management.

  • The medications include phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide.
  • Obesity is classified as a chronic disease, suggesting the need for sustained treatment.
  • Data from phase 3 clinical trials contributed to the approval of these medications.
  • The article reviews clinical indications, how each medication works, dosing, side effects, drug interactions, and contraindications.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Disclosure S.H. Schmitz reports no disclosures. K.H. Saunders reports having equity interest in Intellihealth. L.J. Aronne reports receiving consulting fees from/and serving on advisory boards for Altimmune, Atria, Eli Lilly, Jamieson Wellness, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Juvena Therapeutics, Kallyope, Novartis, Novo Nordisk, Pfizer, Prosciento, Senda Biosciences, Versanis, Veru Pharmaceuticals, and Zealand Pharmaceuticals; receiving research funding from AstraZeneca, United Kingdom, Eli Lilly, Janssen Pharmaceuticals, Belgium, and Novo Nordisk, Denmark; having equity interests in ERX Pharmaceuticals, Intellihealth, Jamieson Wellness, Kallyope, Myos Corp, and Veru Pharmaceuticals; and serving on a board of directors for ERX Pharmaceuticals, Intellihealth, and Jamieson Wellness.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free